#Neuraxpharm and #MinoryxTherapeutics' #Nezglyal has become the first approved drug therapy in the #EU for rare #neurodegenerativedisease #cerebraladrenoleukodystrophy (cALD), and is set to launch before the end of the year.
@pharmaphorum.bsky.social